Imperial College London

Dr Matthew R. Lewis

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Honorary Senior Research Officer







660Sir Alexander Fleming BuildingSouth Kensington Campus





As head of the section of Bioanalytical Chemistry, I oversee a talented and diverse team of experts responsible for the development and application of novel analytical methodology for global profiling and targeted analysis of small molecules, peptides, lipids and proteins. Our principal application space includes human biofluids and tissue extracts as well as the animal models and cell cultures needed to explore disease mechanisms in greater depth. Our favoured technology platforms include nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC-MS) and LC-tandem mass spectrometry (LC-MS/MS). We are most active in the areas of:

  • Analytical method development
  • Technology development and refinement
  • Data extraction and pre-processing workflows
  • Data quality control and monitoring
  • Metabolite assignment and identification including structure elucidation

Together we work closely with clinicians, epidemiologists, and basic science researchers at Imperial to provide innovative and reliable bioanalytical solutions for metabolomics, lipidomics, and proteomics.

As the Chief Operations Officer for the National Phenome Centre (NPC), I am responsible for operational management and delivery of a wide portfolio of research collaborations. Within the NPC, our focus is split between meeting the needs of high precision analysis demanded by large sample cohorts from molecular epidemiology studies, and those of studies involving smaller clinically derived cohorts analysed using both established and developing technologies. 



Goldswain H, Dong X, Penrice-Randal R, et al., 2023, The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection, Genome Biology, Vol:24, ISSN:1474-7596

Kowalka AMM, Alexiadou K, Cuenco J, et al., 2023, Commentary on "The road to reliable peptide assays is paved with good guidelines", Clinical Endocrinology, ISSN:0300-0664

Stebbing J, Takis PG, Sands CJ, et al., 2023, Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS), Oncogene, Vol:42, ISSN:0950-9232, Pages:825-832

Sarmad S, Viant MR, Dunn WB, et al., 2023, A proposed framework to evaluate the quality and reliability of targeted metabolomics assays from the UK Consortium on Metabolic Phenotyping (MAP/UK), Nature Protocols, ISSN:1754-2189

Alexander JL, Mullish BH, Danckert NP, et al., 2023, The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients, Ebiomedicine, Vol:88, ISSN:2352-3964

More Publications